Safwan appointed by Boehringer Ingelheim as new distributor for Kuwait

Safwan Trading & Contracting Co. is one of the top leading companies in Kuwait in the health care business


Kuwait: Safwan Trading & Contracting Co., a subsidiary of Ali Abdulwahab Al Mutawa Commercial Co. (AAW), announced today it was appointed by  Boehringer Ingelheim (BI), one of the world’s leading pharmaceutical companies, as its exclusive distributor for the Kuwait market.

The agreement was signed at AAW headquarters in a ceremony attended by Safwan and BI representatives, including AAW Chairman and CEO Mr. Faisal Ali Al Mutawa, Safwan COO Officer Dr. Dina Younan, Safwan Pharma Manager Dr. Tony Gerges, Safwan Regulatory, PV and Tenders Manager Dr. Absullah Al-Enezi, BI General Manager & Head of Human Pharma of GulfIP Mr. Mazen Bachir, BI National Sales Manager Mr. Hany El Kasaby.

AAW Chairman and CEO Mr. Faisal Ali Al Mutawa, said: “We are honored to be partnering with an international and world-renowned company like Boehringer Ingelheim. This partnership enables us to further develop the pharmaceutical sector in Kuwait and continue to provide the market with new medical and pharmaceutical products.”

General Manager & Head of Human Pharma of GulfIP Mr. Mazen Bachir, said: “Through our partnership with Safwan Trading & Contracting we are strengthening BI’s position towards better serving our customers and all of Kuwait’s residents. This is also in line with the country’s national programme designed to ensure the continued provision of quality healthcare with the support of the private sector. We are very proud of our local teams who have worked relentlessly towards a smooth transition, laying the foundations for a bright future ahead of our organization. We are privileged to have the opportunity to support Kuwait towards delivering its social commitment to provide top-notch universal healthcare”.

Safwan Trading & Contracting Co. is one of the top leading companies in Kuwait in the health care business, representing a considerable number of well-known multinational principals. Safwan has been in business since 1967 and is recognized as a major supplier of pharmaceuticals, medical equipment and supplies, and laboratory products; from the health care sector to the Ministry of Health & other ministries, as well as public and private institutions. In 2005, Safwan was placed as the first company in its category to be enlisted in the Kuwait Stock Exchange.


About Ali Abdulwahab Al Mutawa Commercial Co. (AAW):

Ali Abdulwahab Al Mutawa Commercial Co. (AAW) is one of the largest trading and commercial companies in Kuwait, operating in seven diverse business sectors and distributes in Kuwait’s surging wholesale, retail and consumer market over 100 different global brands, including world-class brands such as Procter and Gamble, Clorox, Roche, Takeda, Biotronik, Nuxe, Bioderma, Nolte Group, La Cornue, Bosch, Siemens, The North Face, Coleman, Nike Store, The Athlete’s Foot, Crocs, Puma,Reebok, among many others.

AAW’s continuously growing business lines include Consumer Goods, Furniture, Kitchens, Home Appliances, Outdoor Gear and Equipment, Sports and Fashion, Real Estate, and Pharmaceuticals where it is a leading wholesale and retail distributor of pharmaceutical and medical products. It also holds a renowned portfolio of principals like Pfizer and Novo Nordisk distributed through its subsidiary Safwan Trading and Contracting (Safwan).

For more information, please visit: 

About Boehringer Ingelheim:

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros corresponded to 18.1 percent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards humankind and the environment.

For more information, please visit the company’s social media platforms for the region: Facebook or Twitter.

For media inquiries, please contact: Nour Samawi  |  +965 99981334  | 

© Press Release 2019

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.

More From Press Releases